Efficacy and Safety of Valemetostat in Relapsed/Refractory Adult T-Cell Leukemia/Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma
Blood 2022 Sep 23;[EPub Ahead of Print], K Izutsu, S Makita, K Nosaka, M Yoshimitsu, A Utsunomiya, S Kusumoto, S Morishima, K Tsukasaki, T Kawamata, T Ono, S Rai, H Katsuya, J Ishikawa, H Yamada, K Kato, M Tachibana, Y Kakurai, N Adachi, K Tobinai, K Yonekura, K IshitsukaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.